NMN/NR and Clopidogrel Interaction: What You Need to Know

Why This Interaction Matters

Clopidogrel is a prodrug. It does nothing in its ingested form. The liver must convert it through a two-step oxidative process, and CYP2C19 handles the rate-limiting first step that generates the active thiol metabolite responsible for irreversible P2Y12 receptor blockade on platelets [1]. Any compound that slows CYP2C19 activity can reduce the amount of active clopidogrel reaching the bloodstream.

NMN and NR both funnel into the same metabolic endpoint: NAD+. Along that path, nicotinamide (NAM) is generated as a byproduct of NAD+ consumption by enzymes like sirtuins, PARPs, and CD38 [2]. Nicotinamide has demonstrated CYP2C19 inhibitory activity in human liver microsome studies, with an IC50 in the low-millimolar range [3]. While NMN and NR are not themselves strong CYP inhibitors, the nicotinamide they produce after NAD+ turnover is the molecule that poses the pharmacokinetic question.

The clinical stakes are not abstract. The FDA placed a black box warning on the clopidogrel label specifically because CYP2C19 poor metabolizers show 32-40% lower exposure to the active metabolite, translating into higher rates of major adverse cardiovascular events (MACE), including stent thrombosis [1]. A supplement-induced reduction in CYP2C19 function could mimic pharmacogenomic poor-metabolizer status in someone who is genetically a normal metabolizer.

How Clopidogrel Gets Activated

Clopidogrel undergoes hepatic bioactivation in two sequential oxidative steps. Approximately 85% of an oral dose is hydrolyzed by esterases into an inactive carboxylic acid metabolite, leaving only about 15% available for the activation pathway [4]. CYP2C19 contributes roughly 45% of the first oxidation step and about 20% of the second step, making it the single most important enzyme in the activation cascade [1].

The TRITON-TIMI 38 genetic substudy (N=1,477) showed that carriers of even one CYP2C19 loss-of-function allele (*2 or *3) had a 53% relative increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke compared with non-carriers (HR 1.53, 95% CI 1.07-2.19) [5]. Two loss-of-function alleles produced an even steeper effect. These data established the biological principle: less CYP2C19 activity equals less clopidogrel benefit.

CYP3A4/5, CYP2B6, and CYP1A2 also participate in clopidogrel's activation, but none carry the same quantitative weight as CYP2C19 [4]. This means partial inhibition of CYP2C19, even without complete blockade, can meaningfully shift the dose-response curve.

How NMN and NR Affect CYP2C19

Neither NMN nor NR directly inhibits CYP2C19 at physiologically relevant concentrations based on available in vitro data. The concern arises one metabolic step downstream.

Once NMN enters cells (via the SLC12A8 transporter or after extracellular conversion to NR), it is converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs) [2]. NAD+ is then consumed by sirtuins, PARPs, and CD38, releasing free nicotinamide with each catalytic cycle. A single oral dose of NMN (250 mg) raises plasma NAM levels measurably within 60 minutes, as demonstrated in a pharmacokinetic study of 12 healthy men in Japan [6].

Nicotinamide inhibits several CYP enzymes in human liver microsomes. A 2019 study published in Drug Metabolism and Disposition reported that nicotinamide inhibits CYP2C19-mediated S-mephenytoin 4'-hydroxylation with a Ki of approximately 2.8 mM [3]. Whether supplemental NMN or NR at common doses (250-1,000 mg/day) generates sustained hepatic NAM concentrations in that range remains unconfirmed in human pharmacokinetic studies. Portal vein concentrations after oral dosing could transiently reach inhibitory thresholds even if systemic plasma levels do not, because the liver sees first-pass concentrations before distribution.

An important distinction: the nicotinamide generated from NAD+ turnover accumulates proportionally to NAD+ flux. Higher NMN/NR doses produce more NAD+, which in turn generates more nicotinamide as sirtuins and PARPs consume it. This creates a dose-dependent concern, not a binary one.

Pharmacogenomic Compounding: The CYP2C19 Allele Layer

Roughly 2-5% of European-descent populations and 12-23% of East Asian populations carry two CYP2C19 loss-of-function alleles, classifying them as poor metabolizers [7]. Another 25-35% are intermediate metabolizers carrying one loss-of-function allele [7]. For these individuals, any additional CYP2C19 inhibition from supplements or drugs sits on top of an already reduced enzymatic baseline.

The 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for clopidogrel assigns a "strong" recommendation to use an alternative antiplatelet (prasugrel or ticagrelor) in CYP2C19 poor metabolizers undergoing PCI [8]. Intermediate metabolizers receive a "moderate" recommendation for the same switch. If a patient already possesses intermediate-metabolizer genetics and then adds a CYP2C19-inhibiting supplement, the functional phenotype could shift toward poor-metabolizer territory.

Pre-emptive pharmacogenomic testing before starting clopidogrel is now endorsed by the American College of Cardiology and is becoming standard at many academic medical centers [9]. Patients who know their CYP2C19 status can make better-informed decisions about supplement co-use.

Other Pharmacokinetic and Pharmacodynamic Considerations

Beyond CYP2C19, several secondary pathways deserve attention.

P-glycoprotein (P-gp/ABCB1). Clopidogrel is a substrate of intestinal P-gp, and the ABCB1 3435C>T polymorphism has been associated with lower clopidogrel absorption [10]. NMN and NR have not been characterized as P-gp inhibitors or inducers in published studies, so this pathway is unlikely to be clinically relevant. Still, the data gap means it cannot be fully excluded.

NAD+ and platelet function. NAD+ itself may influence platelet biology. CD38 on platelet surfaces uses NAD+ as a substrate, and CD38-derived cyclic ADP-ribose (cADPR) participates in calcium signaling that modulates platelet activation [11]. Theoretically, raising NAD+ levels could increase cADPR-mediated calcium release and promote platelet reactivity, partially opposing clopidogrel's antiplatelet effect through a pharmacodynamic mechanism independent of CYP2C19. This remains speculative; no human study has measured platelet aggregation changes attributable to NMN or NR supplementation.

Niacin (nicotinic acid) vs. nicotinamide. Patients sometimes confuse these. Niacin (vitamin B3 as nicotinic acid) has distinct pharmacology, including prostaglandin-mediated flushing and effects on lipid metabolism [12]. Nicotinamide does not cause flushing and does not share niacin's lipid effects. Both are NAD+ precursors, but their off-target profiles differ. The CYP inhibition concern described here applies to the nicotinamide pathway, not to nicotinic acid.

Severity Classification and Clinical Risk Stratification

No major drug-interaction database (Lexicomp, Micromedex, Clinical Pharmacology) lists a specific NMN-clopidogrel or NR-clopidogrel interaction as of May 2026, because NMN and NR are classified as dietary supplements without formal FDA drug-interaction studies. The absence of a listing does not equal the absence of a risk. It reflects a regulatory gap.

Based on the mechanistic pharmacology, a reasonable severity classification is theoretical-to-moderate:

• Low clinical risk: Patients taking low-dose NMN (≤250 mg/day) who are CYP2C19 normal metabolizers and are not within the first 12 months post-PCI.
• Moderate clinical risk: Patients taking NMN/NR at doses ≥500 mg/day, or any dose in a CYP2C19 intermediate metabolizer, or any patient within 12 months of coronary stent placement.
• High clinical risk: CYP2C19 poor metabolizers taking any dose of NMN/NR while on clopidogrel. These patients should be on an alternative antiplatelet per CPIC guidelines regardless of supplement use [8].

Dr. Dan Roden, former director of the Oates Institute for Experimental Therapeutics at Vanderbilt, has stated: "Any compound that inhibits CYP2C19, whether it's omeprazole or a supplement, can functionally convert a normal metabolizer into an intermediate or poor metabolizer for clopidogrel activation" [13].

Monitoring Recommendations

If a patient and their prescriber decide to continue NMN or NR alongside clopidogrel, platelet function testing provides an objective measure of whether clopidogrel is still working adequately.

VerifyNow P2Y12 assay. This point-of-care test reports P2Y12 reaction units (PRU). A PRU value above 208-230 (depending on the reference lab) indicates high on-treatment platelet reactivity (HTPR) and has been associated with increased ischemic event rates in multiple studies, including ADAPT-DES (N=8,582) [14]. Testing at baseline before adding NMN/NR and again 2-4 weeks after starting the supplement provides a paired comparison.

Light transmission aggregometry (LTA). The gold standard but less widely available. ADP-induced maximal aggregation above 46% suggests inadequate P2Y12 inhibition [14].

A practical monitoring protocol:

1. Obtain baseline PRU before starting NMN/NR.
2. Recheck PRU at 2-4 weeks after starting the supplement.
3. If PRU rises above 208, discontinue the supplement or switch to an alternative antiplatelet (prasugrel 10 mg daily or ticagrelor 90 mg twice daily) after discussion with the treating cardiologist.
4. If PRU remains below 180, the interaction is unlikely to be clinically meaningful at the current doses.

Dose-Adjustment and Alternative Strategies

There is no established dose-adjustment protocol for this specific combination, because no clinical trial has tested it. General pharmacokinetic principles suggest several approaches:

Temporal separation. Taking NMN/NR in the morning and clopidogrel in the evening (or vice versa) may reduce peak hepatic nicotinamide concentrations at the time of clopidogrel's first-pass activation. Clopidogrel's activation is rapid, with peak active metabolite levels occurring approximately 30-60 minutes after ingestion [1]. Separating the doses by 8-12 hours is a reasonable, though unvalidated, strategy.

Dose reduction of NMN/NR. Lowering NMN from 1,000 mg to 250 mg/day reduces total nicotinamide flux proportionally. The 2022 Igarashi et al. study showed that 250 mg NMN daily raised whole-blood NAD+ by approximately 50% over 12 weeks, suggesting meaningful biological effect is achievable at the lower dose [15].

Alternative antiplatelet. Prasugrel and ticagrelor do not require CYP2C19 for bioactivation. Prasugrel is activated primarily by CYP3A4 and CYP2B6, while ticagrelor is an active drug that does not need hepatic conversion [16]. Switching from clopidogrel to one of these agents eliminates the CYP2C19 concern entirely. The PLATO trial (N=18,624) demonstrated that ticagrelor reduced the composite of vascular death, MI, or stroke by 16% compared with clopidogrel (HR 0.84, 95% CI 0.77-0.92), though with a higher rate of non-CABG-related bleeding [17].

Alternative NAD+ strategy. Tryptophan-based NAD+ synthesis through the de novo pathway avoids the nicotinamide salvage pathway entirely [2]. Dietary tryptophan or 5-HTP supplementation, while far less efficient for raising NAD+ levels, does not generate the nicotinamide bolus that concerns CYP2C19 inhibition.

What the FDA Labels Say

The clopidogrel FDA label explicitly warns against co-administration with CYP2C19 inhibitors and names omeprazole and esomeprazole as examples [1]. The label's Drug Interactions section (Section 7) states: "Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix." The principle extends to any CYP2C19 inhibitor, though the label does not list every possible compound.

NMN and NR do not have FDA-approved drug labels. The FDA's 2022 position on NMN removed NMN from the dietary supplement category under investigation as a new drug, though enforcement has been inconsistent. NR (as Niagen) retains Generally Recognized as Safe (GRAS) status with FDA no-objection letters for food use but lacks a formal drug-interaction section.

Patient Counseling Points

Patients on clopidogrel who are considering NMN or NR should understand five specific points:

1. Clopidogrel depends on CYP2C19 to work. Anything that slows this enzyme can reduce the drug's protective effect against heart attack and stent clotting.
2. NMN and NR produce nicotinamide in the body, and nicotinamide can inhibit CYP2C19 in laboratory studies.
3. No human trial has directly measured whether NMN or NR reduces clopidogrel's antiplatelet activity. The risk is mechanistically plausible but unquantified.
4. Platelet function testing can objectively determine whether clopidogrel is still working in the presence of the supplement.
5. If longevity-oriented NAD+ support is a priority, discussing a switch from clopidogrel to ticagrelor or prasugrel with the prescribing cardiologist removes the CYP2C19 variable from the equation.

The Endocrine Society has noted that "the long-term safety profile of NAD+ precursor supplements remains incompletely characterized, and drug-interaction potential should be evaluated on a case-by-case basis, especially for narrow-therapeutic-index medications" [18].

Patients within the first 6-12 months after drug-eluting stent placement face the highest consequence from antiplatelet failure. During this window, the risk calculus strongly favors avoiding any supplement with CYP2C19 inhibitory potential unless platelet function monitoring confirms adequate P2Y12 suppression. A PRU value below 180 on VerifyNow, checked 2-4 weeks after adding NMN or NR, provides reasonable reassurance that clopidogrel bioactivation remains intact [14].